Keywords
How to Cite
Abstract
Among evidence based medicine oriented to individual clinical practice, and health technology evaluation (HTE), support for decision making in health; there is a long way to go. HTE is a bridge between the research field and the world of decision making, in particular health policies.
Called the 4th barrier, economic evaluation (EE) is a part of HTE that involved resource allocation. It’s referred to the comparison of alternatives taking account the benefits (health gains, quality of live, years of live, etc.) that each one of them contribute and their costs (necessary resources) to choose the most rentable option for the entire society.
There are assisted prescription models based on a rational use of innovate drugs using evidence and efficiency criteria, developed through Clinical Practice Guidelines and with a continuous evaluation of results.
The objective is to evolve in the understanding of those drugs with clinical, financial and social uncertainty to improve the innovation access decisions.
References
2. Pichon‐Riviere A, Drummond M, García Martí S, Augustovski F. Aplicación de la evidencia económica en la evaluación de tecnologías sanitarias y la toma de decisiones sobre asignación de recursos sanitarios en América Latina: Siete temas clave y una propuesta preliminar para su implementación. En prensa, 2020.
3. Budget impact test. NICE technology appraisal guidance. NICE guidance. Our programmes. What we do About. NICE. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
4. Antoñanzas F, Terkola R, Overton P M, et al. Defining and Measuring the Affordability of New Medicines: A Systematic Review. Pharmacoeconomics 35, 777–791, 2017.
5. ACCC 2017 Survey Shows Cost of Treatment Is Top Threat to Cancer Program Growth. By The ASCO Post 2018. http://www.ascopost.com/News/58453?email=4ca62bcd0ff4b-
12632db3aed949e76127964b1f933d6ad46c-2388fec49c68fda
6. Tremblay D et al. Collaborative governance in the Quebec Cancer Network: a realist evaluation of emerging mechanisms of institutionalization, multi-level governance, and value creation using a longitudinal multiple case study design. BMC Health Serv Res. 2019; 19(1):752.
7. Kilgore K et al. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs. Presented at the 61st American Society of Hematology Annual Meeting and Exposition, Orlando, Florida; December 7-10, 2019; Abstract 793. ash.confex.com/ash/2019/webprogram/Paper124364.html
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar